FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a stable pharmaceutical combined composition comprising metformin, used to treat non-insulin dependent diabetes, and an HMG-CoA-reductase inhibitor used to treat dyslipidemia, as well as a method for producing the stable combined composition.
EFFECT: invention makes it possible to obtain the composition with an effectively improved stability by providing a stable release of the corresponding active ingredients and blocking the physical and chemical interactions between the active ingredients.
16 cl, 3 dwg, 13 tbl, 14 ex
Authors
Dates
2018-04-19—Published
2014-07-25—Filed